跳转至内容
Merck
CN
所有图片(3)

文件

安全信息

SAB5600047

Sigma-Aldrich

兔抗BRAF (V600E)单克隆抗体

recombinant, expressed in HEK 293 cells, clone RM8, purified immunoglobulin

别名:

Anti-B-RAF1, Anti-B-raf, Anti-BRAF-1, Anti-BRAF1, Anti-NS7, Anti-RAFB1

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352203
NACRES:
NA.41

重组

expressed in HEK 293 cells

质量水平

抗体形式

purified immunoglobulin

抗体产品类型

primary antibodies

克隆

RM8, monoclonal
recombinant monoclonal

形式

buffered aqueous glycerol solution

种属反应性

human

浓度

~1 mg/mL

技术

ELISA: 0.5-2 μg/mL
immunoblotting: 0.5-2 μg/mL
immunocytochemistry: 0.5-5 μg/mL
immunohistochemistry: 0.5-5 μg/mL

同位素/亚型

IgG

NCBI登记号

UniProt登记号

运输

wet ice

储存温度

−20°C

靶向翻译后修饰

unmodified

基因信息

human ... BRAF(673)

相关类别

一般描述

BRAF(B-Raf 原癌基因)是一种丝氨酸-苏氨酸激酶,编码 B-Raf 蛋白。它位于人类染色体7q34上。

特异性

该抗体与BRAF V600E突变体反应。与野生型BRAF无交叉反应。

免疫原

对应于BRAF V600E突变体的肽

生化/生理作用

BRAF(B-Raf 原癌基因)参与细胞生长的直接信号传导。它通过在皮肤黑色素瘤、甲状腺癌和结肠癌等各种肿瘤中启动丝裂原活化蛋白激酶 (MAPK) 途径,诱导肿瘤生长。

特点和优势

请完全放心地评估我们的抗体。如果抗体在您的研究中无效,我们将全额退款或换货。了解更多。

外形

溶于含有50%甘油、1%BSA和0.09%叠氮化钠的磷酸盐缓冲盐水中。

免责声明

除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

Not finding the right product?  

Try our 产品选型工具.

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

常规特殊物品
含少量动物源组分生物产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Maria Russi et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 180, 106311-106311 (2022-10-24)
Two clinically approved anticancer drugs targeting BRAF in melanoma patients - dabrafenib (DAB) and vemurafenib (VEM) - have been successfully encapsulated into nanomicelles formed upon self-assembly of an amphiphilic dendrimer AD based on two C18 aliphatic chains and a G2
Daniel Delev et al.
Scientific reports, 10(1), 96-96 (2020-01-11)
Long-term epilepsy-associated tumors (LEATs) represent mostly benign brain tumors associated with drug-resistant epilepsy. The aim of the study was to investigate the specific transcriptional signatures of those tumors and characterize their underlying oncogenic drivers. A cluster analysis of 65 transcriptome
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E, et al.
British Journal of Cancer, 117(10), 1450-1450 (2017)
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ, et al.
Medicine, 96(48), e8404-e8404 (2017)
Xuhong Wang et al.
Oncology letters, 18(1), 927-935 (2019-07-11)
Keratin 19 (KRT19) is a type I cytokeratin that serves an important role in multiple types of cancer; however, little is known regarding its role in thyroid cancer. Therefore, the aim of the current study was to investigate the role

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门